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ABSTRACT
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4-Isoxazolyl-1,4-dihydropyrirines bind the multidrug-resistance transporter
Chairperson: Nicholas R. Natale
The development of multidrug resistance in tumor cells has been recognized as a
major obstacle to successful cancer treatment. Tumor cells in vitro and in vivo can
develop multidrug resistance (MDR) to the lethal effects of a variety of cytotoxic drugs
used to treat cancerous tumor cells. The over expression of multiple drug resistance gene
1 has been correlated with the expression of multi drug resistance protein 1(MDR1, also
known as P-glycoprotein or P-gp). MDR1's role in altering uptake, distribution and
bioavailability is considered a significant factor when examining drugs for clinical
administration, and represents a viable drug target for the reversal of MDR.
MDR1 is driven by ATP hydrolysis and as such it shares both sequence and
structural homology with proteins that are energy-dependent efflux transporters driven by
ATP hydrolysis, making MDR1 a member of the ATP binding cassette (ABC) super
family. Because, MDR1 transports substrates that are often toxic xenobiotics, MDR1 is
thought to fulfill a cellular detoxification function. As such it is expressed in several
tissues in the body such as the liver, pancreas, kidney, colon, intestinal mucosa, and in the
blood brain barrier. Due to its presences in a wide variety of cells it has been suggested
that MDR1 is involved in protection of the organism as a whole. Consequently, the
overproduction of MDR1 is seen in cancer cells. MDR1 has been shown to transport a
wide variety of lipophilic agents, of importance, MDR1 effluxes chemotherapeutics
agents out of the cell resulting in a low and ineffective intracellular drug concentration.
Thus, the over production of MDR1 in cancer cells can then be thought of as a protective
factor for cancer cells, and as an effect causes MDR cancer cells. Therefore,
understanding MDR1’s function is important for controlling the bioavailability of drugs
and for improving anticancer chemotherapy.
Reversal of multidrug resistance is of interest, and MDR reversing agents have been
under intensive investigation. The 4-Isoxazolyl-1, 4-Dihydropyridines (IDHP’s) have
been shown to exhibit inhibition of MDR1. A novel series of IDHP compounds have
been prepared and found to inhibit MDR1. The synthesis, MDR1 assay results, and
relevant controls will be discussed. If successful, halting the function of MDR1 will stop
the outward efflux of chemotherapeutic agents. In combination with chemotherapeutic
treatments IDHP agents could allow for greater effectiveness of pharmaceutical
intervention. This research would give an option in the treatment of cancer that would
normally never exist for MDR cancer patients, and would allow for far more effective
treatment via pharmaceutical means.
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Chapter 1:
MDR1 Background: Why do we care about MDR1 and what does
it have to do with cancer
1.1 The ABC Superfamily
The mammalian multidrug efflux pump Multidrug-Resistance Protein 1 (MDR1)
is a membrane transporter that is the most widely studied member of the ABC super
family of proteins. This 170 kDA protein is most commonly observed in cells that are
over expressing the multiple drug resistance gene 1 (MDR-1) or ABCB1 gene. MDR1
was first identified in Chinese hamster ovary cells that were selected for colchicines
resistance.[1] These cell developed into multiple drug resistant(MDR) cell lines that had a
reduced rate of drug uptake. [1] The ABC super family is the largest protein family in
many organisms, and the family of transporters carries out a wide variety of processes in
both prokaryotes and eukaryotes. [2] Over 80 ABC proteins have been seen in E.coli [3]
and 48 analogous proteins have been observed in the human genome.[4] ABC proteins are
typically composed of four course domains: two α-helical transmembrane domains
(TMD), and two cytoplasmic nucleotide binding domains (NBD) that hydrolyze ATP. [5]
In eukaryotes, the four domains are commonly expressed as a single polypeptide, while
in prokaryotes they are synthesized as two or four separate subunits depending on the
area of expression.[5]
Bacterial ABC proteins have been shown to have importer and exporter
characteristics, while mammalian ABC proteins are exclusively exporters by nature. [6]
All of the ABC proteins have been shown to actively transport substrates against their
concentration gradient. [6] Most ABC transporters have been shown to have broad
substrate specificity, with MDR1 and the breast cancer resistance protein (BCRP) being
the most important clinically. Due to the clinical significance of the ABC proteins they
1

have been studied extensively in the hopes of reversing the MDR phenomenon.
Mutations in 17 different human ABC transporters have been implicated in several
disease states to date, [7] making the identification and examination of compounds that
will selectivity inhibit these transporters of clinical interest.
1.2 MDR1’s Physiological and Pharmacologically Important
The multidrug ATP- binding cassette (ABC) transporters mediates the ATP
dependent efflux of cytotoxic agents out of the cell and away from their intercellular
targets. [8] There are several members of the ATP driven transporters that are expressed at
varying tissue barriers found thought out the body thus, the ABC binding cassette super
family has a profound influence on the uptake and elimination of drugs. [9] Low levels of
MDR1 expression have been observed in most tissues, however, MDR1 is the most
abundant in the apical membranes or polarized epithelial cells with excretory function,
such as, the intestine, kidney, liver and pancreas.[10][11] MDR1 is also located in the
endothelial cell membrane of blood-tissue barriers, including the blood-brain barrier
(BBB), placenta, blood-testis, blood ovary and blood-nerve barriers. [12] The tissues where
MDR1 is expressed are important barriers in the absorption, distribution, metabolism and
elimination (ADME) of many clinically important drugs, including those used in
chemotherapy treatment. The exact physiological role of MDR1 in each of these tissues is
not known with certainty and is complicated by the multiplicity and promiscuity of
substrates that MDR1 can bind. It is though that MDR1 may play a role in protecting the
body from toxic compounds and is considered a cellular “vacuum cleaner” for both
endogenous toxins and xenobiotics. This protective factor is seen experimentally as well.
Experiments with double –knockout mice, mice that don’t express MDR1, but still
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display a normal phenotypes where exposed to ivermectin. Ivermectin is an anti-parasitic
agent; it binds and activates glutamate-gated chloride channels in the CNS. Ivermectin
will lead to ataxia and death if given in high doses. Given that MDR1 was not present in
the double –knockout mice the ivermectin was allowed access into the CNS and the mice
died.[13] While the wild type mice, mice that have MDR1, survived. [13] The knockout
mice couldn’t expel the neurotoxic ivermectin which accumulated in the brain, whereas
wild type mice where protected by the presence of MDR1 in the BBB. This can also be
observed in non-knockout animals, Collie’s (Canis familiaris) especially rough and
smooth Collies, have a naturally occurring fame shift mutation that result in a lack of
MDR1 expression. As one would expect they also display high sensitivity to ivermectin
relative to other breeds of dogs. [14]
Originally the ABC super family has been linked to development of multidrug
resistance in tumor therapy. [20] [21] As mentioned the mammalian MDR1 is an ATPdriven pump that transports structurally unrelated compounds, which include many
anticancer and antimicrobial agents. [22][23] Thus, MDR1 has a vital pharmacologically
role in conferring drug resistance to cells by catalyzing the efflux of these cytotoxic
compounds. [7,15-18] It has become clear that MDR1 can transport many chemically and
structurally unrelated drugs and agents [24], resulting in the MDR phenomenon that
accounts for chemotherapeutic failure seen in the treatment of cancer. Due to this
observation MDR1 has also been recognized as an important factor in novel drug
development, so much that the Food and Drug Administration (FDA) suggested that new
drug candidates should be routinely be screened for MDR1 interactions. [19]
1.3 MDR1 and Multidrug Resistance
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Tumor cells can become resistant to a wide range of anti-cancer drugs in a condition
known as MDR. The development of MDR in tumor cells has been recognized as one of
the major obstacles to successful cancer treatments. [25][26] It has been observed that
MDR1s occurrence is a precursor for the development MDR. [27-29] There are thirteen
known ABC transporters including MDR1, that have been reported to be involved in the
development of MDR. [30] MDR can arise from a variety of cellular mechanisms
including altered drug metabolism, p53 mutation an altered DNA repair processes, but
drug efflux resulting from MDR1 over expression is thought to be one of the core causes.
[31][32]

MDR1 expression levels are correlated with resistance to several anti-cancer drugs

in the U.S. National Cancer Institute collection of tumor cell lines, and it is believed to
contribute to chemotherapy drug resistance in at least 50% of human cancers.[33][34] Some
cancers, including those of the colon, liver, pancreas and kidney, cell lines that express
high levels of MDR1, tend to be inherently drug-resistant. While others such as leukemia,
myelomas, ovarian and breast cancers most often develop MDR subsequent to
chemotherapy treatment. [35] MDR1 has been reported in many of these tumors and in
some cases, its expression increases after one or more rounds of chemotherapy. [35] Given
the clinically relevant evidence of MDR1 and it role in MDR development it illustrates
the continuing need for a selective MDR1 inhibitor.
Consequently, the overproduction of MDR1 is observed in cancer cells. The over
production of MDR1 in cancer cells can then be thought of as a protective factor for
cancer cells, and a cause of MDR seen in cancer. Therefore, understanding MDR1’s
function is important for controlling the bioavailability of the drugs and for improving
anticancer chemotherapy. MDR1 has been shown to efflux a remarkably broad range of
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substrats, and transport numerous structurally and functionally diverse compounds across
the cell membrane. [36] MDR1 and its ligands are therefore extensively studied both in
respect to reversing multidrug resistance in tumors and for modifying ADME properties
for other novel drug candidates. [37] A novel compound that would hinder MDR1 ability
to efflux chemo selective agents out of cancer cells would allow for the repurposing of
out-of-date agents where resistance has been developed. It also allows chemo selective
agents to be used at lower and safer doses, if co-administration was utilized. The
exploration and validation of this hypothesis will follow in due course.
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Chapter 2:
Computer Modeling of MDR-1 and its uses as a predictive model
2. Computer Modeling
A key method for the prediction of receptor-ligand complexes in the drug
discovery process is molecular docking. [1] The first atomic orbital calculation was done
in the UK in the early 1950[71] since then the process has been refined and is now widely
used as a virtual screening tool in the early stages of drug development. It allows for the
reduction of complicated interactions to be refined down to SARs that directs early
synthetic efforts towards more potent and selective compounds. The docking process
itself involves two phases. The first phase, sampling, covers the generation of ligand
configurations and orientations of a ligand relative to the target binding site. These are
referred to as poses. When receptor flexibility is taken into account, sampling also
involves the variation of the receptor configuration. The second phase, scoring, is a
calculated estimation of the ligand’s binding affinity or activity. When docking is applied
to a library of virtual compounds, the compounds are ranked according to the best scored
poses. This process is called ranking. Scores are calculated by evaluating the free energy
that is estimated from the binding of the receptor-ligand complex. There-by, the
complexity of the receptor ligand interaction is immensely reduced and quantified to
allow for a simplified list of potential target compounds. Most of the contemporary
scoring algorithms focus on enthalpy terms, whereas molecular associations are driven by
enthalpy and entropic effects. Often docking programs used simplified structural
representations and reduce if not neglect protein flexibility as well as the participation of
solvent molecules in binding. Additionally, most docking programs assume a certain
static protonation state and consider a fixed distribution of charges among the atoms. The
lengths and, except for the torsions of rotatable bonds, angles between covalently bonded
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atoms are kept fixed. [2] Even considering the limitations, the predictive power and benefit
of molecular docking has been demonstrated in many studies.
2.1 Computational Chemistry Basics
Molecular docking attempt to assess the standard binding free energy of complex
formation. For the estimation of receptor-ligand interactions the free energy is the most
important thermodynamic characteristic. [24-26] In general, it describes the driving forces
of most biological processes such as the folding of proteins, osmotic forces and the
formation of receptor-ligand complexes. Knowing the basic physics involved in these
processes would enables us to calculate the corresponding binding free energy. However,
the complexity of biological systems renders the exact calculation untenable for truly
realistic biological systems. Despite this, there are many systems where it is possible to
construct a virtual model system that reflects the relevant and inherent properties of the
real target system. [23] Modern computer based techniques use parameter based model
systems and several computational and mathematical “tricks” for the generation of
structural ensembles corresponding to a series of structures that are represent the
dynamical processes seen in biological systems. Such simulations are expected to
correspond to the dynamics of the target system. When such a biological process can be
modeled and covered by the simulated timescales, simulations can be used to
approximate the binding free energy involved in these processes. Nevertheless, the size of
typical biologically systems and the timescales on which drug binding takes place cause
an enormous amount of computational power.
2.2 Scoring Functions

9

The scoring function is one of the central concepts in molecular docking. This
function enables a docking algorithm to rapidly describe and quantify the interactions
between ligand and receptor. During the sampling phase the docking algorithm produces
different ligand configurations and orientations within the target site and assigns a score
by evaluating the scoring function. An ideal scoring function would provide the lowest
scores for the energetically most favorable receptor ligand configurations. Assuming that
these configurations represent the interactions that mainly promote the ligand binding,
they give some insight into the underlying molecular mechanisms. An overview over a
broad spectrum of scoring functions is given, [28] there are mainly three different types of
scoring functions.
Force-field based scoring functions are designed based on underlying physical
interactions such as van der Waals (VDW) interactions, electrostatic interactions they
also take into account the bond stretching, bending and torsional interactions of the
calculated compounds. The force field parameters are usually derived by both fitting to
empirical data and Ab initio calculations. A typical force-field based scoring function is
implemented in the DOCK algorithm whose energy function is the sum of VDW and
coulombic energy contributions:

Here Aij and Bij are VDW parameters, qi and qj the charges and rij is the distance
between the particles i and j this is often referred to as the dielectric constant.[29] The
scoring function does not include the energetic costs of desolvation which is a
consideration for many body interaction terms and depends on the chemical environment.
As such, to account for desolvation, further terms are usually added based on the solvent
10

accessible surface area of the ligand and possibly the receptor.[30] When energy terms of
VDW and coulombic interactions are used in a scoring function, they need to be
empirically weighted, this will account for the difference between energies and free
energies,[31,32] and also account for the different methods used to calculate the varying
terms.
Empirical scoring functions estimate the binding free energy ∆ G of a receptorligand complex by a sum of weighted energy terms:

The energy terms Gi can represent VDW and electrostatic interactions, hydrogen bonding
strength, entropy changes, hydrophobic interactions or desolvation energies and energy
terms. The weighted term ωi is derived from known experimental data of a previous
training set. In 1994 Büohm developed an empirical scoring function consisting of
hydrogen bonds, polar interactions, the lipophilic contact area between ligand and
receptor and the number of rotatable bonds in the ligand.[30] The weighted terms were
calculated with a dataset of 45 protein-ligand complexes.[30] This scoring function was
further improved when Eldridge[31] developed the ChemScore scoring function that
includes terms for hydrogen bonds, metal atoms, lipophilic contacts as well as the
number of rotatable bonds in the ligand. But, due to the number of terms in the empirical
scoring function it becomes more and more difficult to avoid double counting specific
interactions. Thus, the applicability of empirical scoring functions may depend on the
data used in the training set. As such empirical scoring functions that are fitted to larger
training sets should be more generally applicable. Knowledge based scoring functions use
terms that weight the receptor-ligand complexes by the occurrence frequencies of
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particle-particle pairs in a database of known complexes[32]. The idea behind the
knowledge based scoring function is that large numbers of different particles will
somehow distribute themselves into a gas phase at temperature T if the interactions are
purely pair wise, the distributions can be described by the equilibrium pair wise density
ρij (r) between any two particle types i,j at distance r. In this case, the interaction free
energy, wij(r), can be calculated from the observed densities by the inverse Boltzmann
relation:

Where ρij (r) is the pair density of a particle pair at distance r and ρij, the pair density of a
reference state where the inter-atomic interactions are zero[27,32]. Since these potentials
are extracted from the structures rather than from known binding affinities by fitting, and
the training structural database can be large and diverse, the knowledge-based scoring
functions is considered to be more reliable to a given training set[27]. Because of the pair
wise interaction scheme the knowledge based scoring functions can be as fast as the
empirical scoring functions. However, atoms in protein-ligand complexes are not
particles in the gas phase and the frequencies are not independent from each other.
Therefore, the calculation of accurate reference states ρij, is a challenging task in the
development of knowledge based scoring functions.
Hybrid scoring functions are implementations of mixtures of the different flavors
of scoring functions. They combine force field terms and empirical energy terms. This is
done, in the program like eHiTS[33,34]. Notably, all currently applied scoring functions
require a significant degree of empirical fitting. Therefore, scoring functions are not
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necessarily generally applicable to all kinds of drug targets and should be standardized
and possibly optimized.
2.3 Molecular architecture of MDR-1
There are a number of techniques that can be used to derive the structure of a
protein. Including, cryo-electron
microscopy(EM), X-ray crystallography, nuclear
magnetic resonance (NMR), and bioinformatics
based approaches can all aid in the elucidation of
the structure and function of an unknown protein.
Historically, our understanding of drug

Figure 2-1: AMP-PNP

transporter structure originated from single particle and 2D cryo-EM. As such, the first
three dimensional structure of MDR1 was obtained by “two-dimensional” cyo-EM.[5] The
two-dimensional proteins [3,4] were observed in the presence and absence of AMP-PNP, a
non-hydrolyzable analogue of ATP that has been shown to bind to the NBD at the same
site as ATP. Two dimensional cyo-EM trapped MDR1 at different steps of the transport
cycle. These data were interpreted to suggest that the transmembrane α-helixs undergo
conformational changes as a result of the ATP binding, followed by subsequent
hydrolysis and substrate release. [5] This led to many attempts to correctly describe the
conformational change, ultimately leading to the alternating access hypothesis that is
supported today. It was also noted that this conformational change was responsible for
the known efflux phenomenon of the transporter that leads to MDR.
2.4 Topology of MDR1
The mammalian MDR-1 topology, was first described by Danø[35] and Juliano
and Ling.[36] MDR1 is a single 1280 amino acid polypeptide organized into two semi-
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homologous halves. With mammalian MDR1 characterized by 12 transmembrane
domains and two nucleotide binding sites. [47] Each half of the protein contains six
transmembrane domains and one nucleotide binding site for each half. [38] The two semihomologous halves of the protein are separated by an intracellular flexible 60 amino acid
linker polypeptide loop. [38]
In general the two NBD’s have been shown to work in a cooperative matter to
allow for the hydrolyzing of ATP. [39] The binding and hydrolysis of ATP is the energy
source that is used to functionally couple the outward efflux of drugs substrates against
the concentration gradient. [40, 41] Several models have been proposed to explain the
energetic coupling between the NBDs and the efflux of drugs out of the cell. [39] The most
widely accepted model is known as the alternating access or the rocking banana mode of
action.
The common transport of substrates against a concentration gradient via ATP
hydrolysis is a common function of ABC transporting proteins. It is not surprising that
there are shared structural features. As described previously the focus of our research is
the NBD due to the previous observations that DHPs have been shown to bind in this
location. There is also a relatively high degree of conservation between the NBD across
species, which is expected given the common mechanism of ATP driven transport. This
also makes targeting the NBD a promising lead in that most MDR1 proteins will be
affected by competitive binding at the ATP site. NBD1 and NBD2 have 25% and 28%
sequence identity respectively, with a 50% similarity across the ABC superfamily. [42] [43]
The NBD of many proteins that bind and hydrolyze ATP contain a sequence termed the
Walker A and Walker B motifs, [44] with a unique motif, the signature C motif being
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specific to MDR1.[45] MDR1 also contains highly conserved amino acids in the A, Q, H,
and Pro-loop of the NBDs. These loops along with the Walker A and B regions and the
signature C motifs, are involved in the binding and the coordination and hydrolysis of
ATP. [46] The Q and P-loops have also been shown to be involved in the interdomain
communication and coupling ATP hydrolysis to the TMD. [47] It must also be mentioned
that the other potential binding sites in MDR1 don’t show the same level of conserved,
with low level of sequence similarity in the TMDs. This is not surprising due to the
substrate promiscuity of MDR1.
2.5 X-ray Crystal structure of MDR1
Mammalian MDR1 has recently been crystallized [48] (PDB: 3G5U). Earlier
attempts to model the 3D structure of MDR1 suffered from low sequence identity to the
template protein, a prime example being the bacterial ABC transporter MsbA.[49,50] The
high resolution X-ray crystallographic structure are available for the bacterial lipid A
flippase MsbA in several nucleotide bound states,[51] and the transporter Sav 1866 from S.
aureus with bound AMP-PNP.[52,53] Both MsbA and Sav1866 show the highest sequence
similarity with MDR1 of all ABC transporters.
2.6 Sav 1866 as a template
In 2006 the crystal structure of a bacterial ABC transporter, Sav1866 from S.
aureus, was published. [7] The first Sav1866 structure was resolved to 3.0 Å, the structure,
was a MsbA model that was a homodimeric ABC transporter that is semi-homologous to
MDR1. Sav1866 was crystallized in the presence of two adenosine diphosphate (ADP)
molecules that bound at the interface of the NBDs. The NBDs of the Sav1866
homodimer are similar in structure to those of other ABC transporters.[7] These domains
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show conserved ATP binding and hydrolysis motifs at the shared interface in a head-to
tail arrangement. [8-10] In 2007 Locher published the crystal structure of Sav1866
complexed with AMP-PNP. [11] A comparison and superposition of both structures, the
AMP-PNP bound Sav1866 and the ADP bound Sav1866, indicated that these structures
are essentially identical and represents the ATP-bound state of the transporter. The
different structures of MsbA were indicated to be reconcilable with the Sav1866 when
mirrored. [12]
The overall architecture differs from the side by side arrangement of the TMDs
and was observed for the ABC transporters BtuCD[13] HI1470/1[14] ModB2C2[15] and
MalFGK2.[16] In the ABC exporters the TMDs interact with the helical domains of the
NBDs through coupling helices that are located in the loops between TM helices.[17] One
intracellular loop of each TMD makes contact with the NBD.[18] The two subunits exhibit
a considerable twist [7] the transmembrane helices of MDR1 diverge into two discrete
points away from one another towards the cell exterior of the membrane, producing what
is known as the inward facing conformation. The inward facing conformation of the
transporter is thought of as its resting phase and after ATP is hydrolyzed it transitions
into its active phase. This alternative conformation is seen when helices from both TMDs
move away from one another.[7]The helical arrangement observed in Sav1886 is
consistent with this, except for helices 6 and 12, where cross-linking studies have
identified analogous TM helices in human MDR1[7]. Helices 6 and 12 are positioned
closer to each other than in the Sav1866 crystal structure. [19] The arrangement of the 12
canonical transmembrane helices observed for Sav1866 is in agreement with the ABC
exporter topology.[7] Also, they are consistent with electron density maps of human
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MDR1 and cross linking restraints.[20] The ATP bound state of the NBDs, with the two
nucleotide binding domains in close contact, is likely to be coupled to the outward facing
conformation of the TMDs. In this conformation the helices line a central cavity, which is
open to the cell exterior. The three previously published structures from Escherichia
coli, Vibrio cholera and Salmonella typhimurium were revised by Chang. Now all models
show the analogous topology to Sav1866.[23]
2.7 Homology Model of MDR1
In the absence of a high resolution crystal structural for a human MDR1, an
alternative is the generation of a protein homology model. The availability of accurate
crystal structures of closely related target proteins is a critical factor for structural
homology between a structurally resolved protein, and the unknown. Conformation
sequence identity and an identical number of predicted transmembrane spanning helices
are important for the selection of a template modeling of membrane proteins [6]. The
quality of a homology model is determined by the accuracy of the alignment between the
protein of interest and the template protein, and the quality of the crystal structure used as
the modeling template.
2.8 Development of MDR1 Homology Model
With the lack of a reliable Homo sapiens crystal structure, a homology model
based on the inward facing Mus musculus model was constructed.
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Figure 2-2: Human homology model of MDR1

As the structural difference between the apo protein and the co-crystallized
structures was surprisingly low the higher resolved 3G5U structure was utilized as
homology modeling template. The Model of the human MDR1 were created using the
sequence homologies between the Mus musculus (PDB:3G5U) model and the protein
sequence of the Homo sapiens MDR1 (Uniport: P08183). After the alignment of the
sequence with VMD, Modeller 9.4 was then employed to construct 100 different
homology models. The lowest energy homology model was then selected as the human
model of MDR1.
Traditionally, experimental assays are used to assess novel drug candidate’s
interactions [61]. The major drawback to this process is that experimental assays are
expensive and time-consuming. A reliable in silico model would be an invaluable tool to
rapidly and more cost effectively screen potential compounds. This process would
identify MDRR candidates and has been recognized as a valuable tool to those in industry
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[62-64]

. Computational approaches and model based approaches have been attempted but

have only shown limited success [65-73].
Computer modeling was used to provide a convenient means of investigating
aspects of the SAR. This emerging analysis allows for supporting explanations of
pharmacological date from relevant experimental data. Computer modeling also allow for
the ration design of the potential pharmaceutical agents. A number of studies have been
conducted and have given some insight into what novel structures should be pursued [58]
[59]

. In this respect a reliable homology model of MDR1 would be a great asset in drug

discovery [60].
This human model was then utilized to evaluate established SAR that has been
established, along with being the current working model of the remainder of the in silico
studies performed for inhibitors.
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Chapter 3:
4- Isoxazolyl-1,4-dihydropyridines as inhibitors
3.1 MDR1 inhibitors and Current Clinical Trials
There have been a number of compounds that have been identified as MDR1
inhibitors.[1] [2] The majority of these novel compounds that are known to inhibit MDR1
have not yet advanced to being utilized in the clinic due mainly to severe side effects and
lack of selectivity. Never-the-less, reversal of multidrug resistance is of widespread
clinical interest and multidrug-resistance reversers (MDRR) are currently under intensive
investigation. Given MDR1’s involvement in MDR it is a viable drug target for the
reversal of MDR.

Figure 3-1: Known inhibitors of MDR1

First-generation inhibitors such as cyclosporin A, and verapamil suffered from
unacceptable high toxicity, and were dropped as potential inhibitors after phase II clinical
trials. [3] The second-generation agents: valspodar, and biricodar have better toxicity

23

profiles, but showed cross reactivity and unpredictable pharmacokinetic interactions with
other transporter proteins [3]. Third-generation inhibitors such as tariquidar (XR9576),
zosuquidar (LY335979), laniquidar (R101933), and ONT-093 have high potency and
specificity for MDR1. [3] The pharmacokinetic studies to date have shown no significant
interactions with CYP450 3A4 drug metabolism and no clinically significant drug
interactions with common chemotherapy agents. [3] The prevalence of MDR1 expression
in several tissues is proving to be a major issue when considering side effects of potential
inhibitors. It is for this reason that most MDR1 inhibitors have had sub-optimal results in
clinical trials.
4- Isoxazolyl-1,4-dihydropyridines (IDHP) have been known to bind L-type
voltage gated calcium channels, and dihydropyridines (DHPs) have been in general
medical practice for use as anti-arrhythmic agents for decades,[4] and as such the DHPs
has been recognized as a privileged scaffold found in medical chemistry.[5] More recently
however, the DHPs scaffold has been recognized as a substructure to design around to
produce MDRR’s.[6-11] Given that the clinically used DHP such as nicardipine and
niguldipine are known ligands for MDR1. [10-12] We constructed a common
pharmacophore model (Fig. 3-2) to visualize common structure features to direct
synthetic efforts towards more valid analogs. Figure 3-2 shows clinically used 1,4
dihydropyridine nicardipine (cyan), niguldipine (pink).
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Figure 3-2: The overlapping pharmacophore of nicardipine(cyan), niguldipine(pink) and novel IDHP(green)

The spatial conservation of the function groups is apparent, the most apparent
difference being the conformationally unique structure that the isoxazole moiety imparts
to the IDHP. The IDHP allows for more novel and structurally divergent compounds to
expand the library of compounds which have previously been studied, which in turn
could potentially allow for corresponding more divergent and novel pharmacology.
To further study the effect of IDHPs as MDRRs on MDR1 and to aid in further
analog development a binding box for IDHP was needed as a working hypothesis. Given
that MDR1 has a large number of potential substrates we chose to focus our efforts on the
initial characterization of the IDHP binding site. Shown in Figure 3-3 is a space filling
model of MDR-1. The binding sites of interest are known as the DHP binding site resides
near the NBD. It’s shown below (Fig. 3-3) that the yellow spheres represent how ATP
interacts with the NDB, this gives the general areas in which the putative IDHP binding
site is located.
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Figure. 3-3: Model of substrate binding sites of MDR-1. The Rhodamine binding site (cyan) and the alternating axels
motion of the protein is shown. The horizontal bar represents the approximate position of the lipid bi-layer
Reprinted with permission from the publisher.

Shown in Figure 3-4 is a ribbon diagram of MDR-1, the NBD’s are labeled
below as NBD1 and NBD2.

Figure. 3-4: Ribbon Diagram of P-gp. (A) Front and (B) Back stereo view of P-gp. The N- and C-terminal of each half
of the molecule is colored yellow and blue respectfully. The horizontal bar represents the approximant position of
the lipid bi-layer. Reprinted with permission from the publisher

The characterization of the DHP site was first attempted by using domain
mapping experiments. [13] Domain mapping studies in combination with
immunoprecipitation were utilized to identify the DHP binding site.[14] Other studies [15]
have been performed with photo labeled DHP derivatives, the studies showed binding at
two major regions, one in each half of the protein [16]. This suggested that the DHP
derivatives bind to both NBD.
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Figure 3-5: Niguldipine

To further refine the DHP binding site a niguldipine (Fig.3-5) was chemically
modified. The study that we are currently using as a starting point used a photoaffinity
label which replacing the nitro group seen in niguldipine (Fig. 3-5) with an azido group.
Given the previous efforts to identify MDR1 binding sites a mass spectrometric (MS)
approach was utilized in this study.
The first step that was taken to identify the binding site of niguldipine, was to
photolyze the modified DHP in the presence of MDR1. The protein was then solubilized
in detergent. The solubilized protein was then identified via PAGE-SDS gels and purified
via lectin affinity chromatography.[13] For the identification of the protein, Western Blot
analysis was carried out using monoclonal anti-MDR1 antibody C219. [13] The identified
protein was then digested via trypten, but trypten peptides can cleave at 179 possible sites
on the remaining protein so further purification was needed. The protein was then further
purified via HPLC. Three runs on the HPLC shows peaks corresponding to the
niguldipine bound protein, and these fractions where then pooled. The pooled samples
were then analyzed via Matrix-assisted laser desorption/ionization (MALDI). [13] The
sequence containing the DHP bound protein was isolated followed by Edman degradation
and MS analysis to identify the sequence. Edman degradation allowed for the sequential
cleavage of the N-terminal amino acids until the bound niguldipine sequence is
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encountered. Edman coupling combined with MS can then reveal the maximum number
of amino acids that compose the labeled site. The final localization of the niguldipine
binding site in MDR1 was found to be correspond to the sequence 468-527,[13] this is in
agreement with the previous immunoprecipitation experiments that showed the
dexniguldipine binding site in the N-terminal or the cytoplasmic half of MDR1.[17] In
other proposed structural model of MDR1 the niguldipine binding site is also in the
cytoplasm assigned to the sequence 491-526. [18] The results suggest that this region is
near the N-terminal NBD this indicates that the chemo sensitizer binding site and ATP
binding domains interacts with each other. It is known that the drug binding site and ATP
hydrolysis are coupled. [19] Observing that both sequences are closely related to one
another is evidence that this is the correct binding sequence.
Various studies have attempted to locate the drug-binding sites and key residues
responsible for the interaction with ligands. Studies of ligand–ligand interactions on
MDR1 revealed that some ligands interact with the transporter as single molecules,
whereas others interact as pairs.[20]

Figure 3-6: Rhodamine 123

As mentioned above MDR1 contains multiple sites, distinct sites for transport of
rhodamine 123 (R-site) in addition to a modulatory site for prazosin and
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progesterone.[22][30] Binding of ligands at one of these transporters site enhances the
interaction at the others. [22] Equilibrium binding studies on MDR1 provided evidence for
three sites for transported ligands (vinblastine, pacitaxel, and Rhodamine), which can
interact with ligand in the absence of externally added nucleotides, in addition to a
modulatory site for niguldipine/GF120918.[24] The observation that there could be
similarities in both the R-site and the DHP binding site, which could allow for this
cooperation and communication to occur that, could cause the conformational changes
and allow MDR1 to function. Given the previous research on the binding of DHP a
computer model was used to produce a refined ligand binding box.
3.2 Computer Modeling/Virtual Docking
To provide testable hypotheses for binding at the DHP binding site, computer
modeling was employed. A MDR1 human crystallographic structure doesn’t currently
exist, so a homology model was constructed from the published X-ray crystal structure
Mus musculus (pdb accession number: 3G5U) a close homolog of the human ABC
transporter MDR1. A sequence homology was then performed between the known human
MDR1 sequence and the 3G5U followed by threading of the known human MDR-1
sequence into the published X-ray crystal structure. As explained above the binding site
for the DHP has been broadly defined as the resides 468-527.To avoid any bias in further
defining the DHP binding site, the MDR1 human homology model was submitted as the
entire MDR1 transporter to the Q-site finder online server. [37] This software displayed ten
different binding sites on the MDR1 homology model. The program binds hydrophobic
probes to the MDR1 homology model and finds clusters of probes with the most
favorable binding energy. These clusters are placed in rank order of the likelihood of

29

being a binding site according to the sum total binding energies for each cluster. The first
binding cluster was bound in the rhodamine binding site or R-site, the second and third
sites were located inside the NBD. With the characterization of the niguldipine binding
site in place from the photoaffinity binding site study, [13] combined with the output of the
Q-site finder gave a tentative binding site. The overlap of the two sites is considered a
possible binding location for DHP. [39] Figure 3-7 shows the photoaffinity study in red
and the Q-site finder result shown in blue

Figure 3-7: Highlight of the both the photoaffinty binding site (red) and the Q-site
predicted binding site (Blue)
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Figure 3-8: The overlapping amino acid sequence (purple) from the photoaffinity
binding site and the Q-site binding site
The overlapping amino acids from the photoaffinity and the Q-site finder are
shown in purple in Figure 3-8. Given the obvious shape and location of overlapping
amino acids, this defined site can be thought of as a putative binding site for IDHP. With
a binding site in place IDHPs were then used to validate the in silio model. A library of
IDHPs was then studied to validate the binding site, shown in Table 3-1.

Figure 3-9: General Structure of IDHP used for table 1
IDHP

R1

R2

MDR1 (% inh.)

1a

CH3

C6H5

48.9

1b

CH3

o-MeO-C6H4

32.8
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1c

CH3

2-MeO-5-Cl
C6H3

15.0

1d

CH3

o-Cl-C6H4

10.9

1e

CH3

m-Cl-C6H4

26.8

1f

CH3

p-Cl-C6H4

11.7

1g
1h

i-Pr
C6H5
C6H5CH2CH2 C6H5

38.4
27.6

1i

p-Biphenyl
CH2CH2

CH3

18.6

1j

1-naphthyl
CH2CH2

CH3

19.0

1k

m-Br
C6H5CH2
(CH3)CH

CH3

61.2

1l

1-naphthyl
CH3
CH2(CH3)CH

38.3

Table 3-1: IDHP activity at MDR-1
MDR1 screening and the establishment of MDR1 inhibition activity was
performed by the Psychoactive Drug Screening Program (PDSP) of the NIMH. The assay
was performed using live Caco-2 cells, a cell line derived from human colonic epithelium
cell that express MDR-1.[39] The assay uses Calcein-AM which passively diffuses in to
the cell, after which it is hydrolyzed turning the compound fluorescent and adding a
negative charge thus trapping the compound in the cell. Calcien-AM can be effluxed out
of the cell via MDR-1, thus MDR-1 inhibition is a function of the fluorescencet that is
observed. Flourescence is measured using a FlexStation II fluorimeter in a 96 well plate
after preincubation with the given IDHP (50μM for 30min). After which calcein-AM was
then added to a final concentration of 150 μM. Fluorescence was then monitored over 4
minutes, with each assay performed in quadruplicate, with 25 μM cyclosporine used as a
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control. The value of untreated control cells where taken as 0% inhibition and the slope
of the fluorescene is normalized taking the value of cyclosporine at 100%.[40]
With the binding data in hand ligand structures were drawn and energy minimized
(Powell method, 0.01 kcal/mol*A gradient termination, MMFF94s force field, MMFF94
charges, 1000 maximum iterations) using the Sybyl modeling program (Tripos, St. Louis,
MO, USA). Structures were virtually docked into an in silico-activated virtual dockings
of energy minimized ligands to the MDR1 human homology model were performed
using the program GOLD (Cambridge Crystallographic Data Center, Cambridge, UK)
and scored using GOLD Score with default settings. Ligand-receptor ensemble structures
were each obtained by merging the highest ranked docking output ligand orientation
structures with the input MDR-1 human homology model structure using the SYBYL
software package (Tripos, St. Louis, MO), followed by energy minimization, molecular
dynamics, and a final energy minimization simulation. Aggregates for molecular
dynamics and minimization simulations were defined as residues more than 6 Å from the
ligand. Binding was localized around the SER 475, one of the amino acids at the interface
of the overlapping photoaffinty binding and the Q-site finder amino acids (ARG 467,ILE
470, GLY 471, VAL 472, VAL 473, SER 475, GLN 474, GLU 476, PRO 477, VAL 478,
LEU 478, PHE 480, TRY 490, GLU 491). From this analysis three binding site cohorts
were defined from the library of compounds.
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Figure 3-10: The low affinity cohort compounds 1c, 1f, and 1d
Figure 3-10 shows what has been termed the low affinity cohort where
compounds 1c, 1f and 1d bound all of the associated compounds that where bound in this
location never achieved more than 15% MDR-1 inhibition.

Figure 3-11: The medium affinity cohort compounds 1i, 1j and 1l
Figure 3-11 shows what has been termed the medium affinity cohort where
compounds 1i, 1j and 1l bound. Compounds 1i and 1j where bound in the same location
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adjacent to the binding box and never achieved more than 19% MDR-1 inhibition. 1l on
the other hand, bound with a portion of the structure inside the defined binding box, or
the high affinity cohort, this would explain the abnormally high 38% MDR-1 inhibition
that was observed for this binding location.

Figure 3-12: The high affinity cohort, also considered the binding site for IDHP
Figure 3-12 shows what have been termed the high affinity cohort where
compounds 1a, 1b, 1e, 1k, 1g, 1h bound. Compounds that bound in this location had
robust MDR-1 activity with a range varying from 27% to 61% MDR1 inhibition. Most
notably, compound 1k the most active compound in this series is bound here validating
the computational model as a predictive tool. To aide in further development of second
generation MDRRs, 1k was selected and all interactions were examined in a 6 Ǻ radius
around the IDHP structure. The binding box interactions were then divided into regions
to classify the overall interactions that allow for robust binding, the purple amino acids
that are shown represent the overlapping amino acids from the photoaffinity study and Qsite.
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Figure 3-13: Region 1 of compound 1k
Figure 3-13 shows region 1 of compound 1k the majority of the interactions are
liphophilic from Phe 904, Arg 905 and Val 908. There is also polar interaction that where
are observed with the π cloud of the phenyl ring with residues Glu 476, Ser 474, and Val
472.
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Figure 3-14: Region 2 of Compound 1k
Figure 3-14 show region 2 of compound 1k there are liphophilic interactions on
both the methyl groups by residues Phe 480, Val 478 and a polar interaction with Val 472
with the isoxazolyl.
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Figure 3-15: Region 3 of Compound 1k
Figure 3-15 shows region 3 of compound 1k there are multiple interactions with
the DHP nitrogen with the residues Ser 909, Thr 911 and Tyr 490, with additional polar
interactions involving Ser 909, Arg 547 and Arg 543. This region also highlights a key
anchoring point for the compound, the 1, 4-dihydropyridine substructure has been shown
to be key in binding MDR1. Further analog development will be focused on conserving
the 1,4-dihydropyridines substructure while altering other key structural factors in the

38

series. The isoxazolyl has minor anchoring interactions but the spatial arrangement that is
allowed via the inclusion of the isoxazolyl is novel and as such will be conserved in later
analog development. The future IDHP analog development will focus on the modification
of groups adjacent to the isoxazolyl.
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